Moath Alqaraleh; Violet Kasabri; Frezah Muhana; Belal Omar Al-Najjar; Khaled M. Khleifat
Abstract
This study intends to investigate the potential use of mmBCFA, which includes 10 MTD, 12 MTD, 13 MTD, and 14 MTD, as a treatment option for cancer. This is due to the close correlation ...
Read More
This study intends to investigate the potential use of mmBCFA, which includes 10 MTD, 12 MTD, 13 MTD, and 14 MTD, as a treatment option for cancer. This is due to the close correlation between metabolic dysregulation and the mmBCFA presence. We looked at how mmBCFA affected several cancer cell lines, such as those from the pancreas, colon, and breast. After determining the antiproliferative effects of these agents, we evaluated the expression levels of Bax, β-catenin, and cyclin D1. Furthermore, we performed Molecular Docking studies to look into how these agents interacted with the tyrosine kinase (EGFR) domain of the Epidermal Growth Factor Receptor. We discovered that mmBCFA efficiently inhibited the growth of multiple cancer cell lines, such as those from the colon, breast, and pancreas. Specifically, we found that when insulin was stimulated in HCT116, MCF7, and Panc1 cancer cells, 12MTD and 13MTD significantly reduced the expression levels of β-catenin and Cyclin D1. This was determined using selective qRT-PCR methods. In addition, our Molecular Docking analyses indicated that 12 MTD and 13 MTD interacted with specific residues in the EGFR domain. Based on our current findings, it appears that the mmBCFA supplementation could be considered as a novel and promising therapeutic option for treating cancer.
